--- title: "Immunome (IMNM) news: offering" url: "https://aibio.space/companies/immunome/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IMNM offering news: Immunome proposes $400 million stock offering, later sets $21.50 price. Immunome, Inc. (NASDAQ: IMNM), United States." --- IMNM Immunome, Inc. NASDAQ · United States # Immunome (IMNM) news IMNM offering news Financings · 2026-10-05 ## [Immunome pays Bristol-Myers Squibb $20.0 million and 4,425,487 shares to end royalties](https://aibio.space/news/immunome-pays-bristol-myers-squibb-20-0-million-4-425-487-shares-end/) Immunome paid Bristol-Myers Squibb $20.0 million and 4,425,487 shares under Amendment No. 4, which ends its milestone and royalty obligations. The 8-K names no underwriter or placement agent; at June 30, 2026 the company held $217.7 million in cash and equivalents plus $302.3 million in short-term investments. ## Latest Immunome news 1. 2025-12-15 Financings [Immunome proposes $400 million stock offering, later sets $21.50 price](https://aibio.space/news/immunome-proposes-400-million-stock-offering-later-sets-21-50-price/) Immunome said on December 15, 2025 that it planned a $400 million stock offering, and priced it the next day at $21.50 a share. 2. 2025-05-12 Listings [Immunome reports $317.3 million in cash and expects runway into 2027](https://aibio.space/news/immunome-reports-317-3-million-cash-expects-runway-2027/) Immunome's cash total includes $161.7 million from a January 2025 financing, and the quarter ended with a $41.6 million net loss. Its lead drug's Phase 3 data are not due until the second half of 2025. 3. 2024-10-29 Mergers [Immunome buys licensed Zentalis ROR1 assets for 1,805,502 shares](https://aibio.space/news/immunome-buys-licensed-zentalis-ror1-assets-1-805-502-shares/) Immunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement. ## Immunome at a glance - **Ticker**: IMNM - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $520.0 million ### Related companies - [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) NASDAQ: MCRB - [Lineage Cell Therapeutics](https://aibio.space/companies/lineage-cell-therapeutics/) AMEX: LCTX - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) NASDAQ: AXSM - [SORRENTO THERAPEUTICS INC](https://aibio.space/companies/sorrento-therapeutics/) OTC: SRNE - [Surrozen](https://aibio.space/companies/surrozen/) NASDAQ: SRZN - [Oncolytics Biotech](https://aibio.space/companies/oncolytics-biotech/) NASDAQ: ONCY - [City Therapeutics](https://aibio.space/companies/city-therapeutics/) NASDAQ: CTY - [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) NASDAQ: COYA ### Also on NASDAQ - [Personalis](https://aibio.space/companies/personalis/) PSNL - [SeaStar Medical Holding](https://aibio.space/companies/seastar-medical/) ICU - [DEXCOM INC](https://aibio.space/companies/dexcom/) DXCM - [Cabaletta Bio](https://aibio.space/companies/cabaletta-bio/) CABA - [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) PBYI - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) RLMD ## What Immunome does Immunome is a company with antibody-drug conjugate (ADC) and radioligand programs. Its clinical asset varegacestat, formerly AL102, is an investigational, oral, once-daily GSI therapy under evaluation for desmoid tumors. In December 2025, Immunome reported positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors, and the study met all primary and key secondary endpoints. The company is preparing for a potential commercial launch of varegacestat, subject to regulatory approval, and is investing in commercial supply readiness. Its pipeline also includes IM-3050, a fibroblast activation protein targeted radioligand therapy that received IND clearance in April 2025, with a Phase 1 trial planned for early 2026 after delivery of third-party diagnostic radiotracer supply. Immunome has three preclinical solid tumor ADCs, IM-1617, IM-1340 and IM-1335, with IND submissions anticipated in 2026, and it says its discovery approach centers on designing ADCs against novel or underexplored targets. | Product or program | What it is | Stage | |---|---|---| | Varegacestat (formerly AL102) | Oral once-daily GSI therapy for progressing desmoid tumors | Phase 3 | | IM-3050 | Fibroblast activation protein targeted radioligand therapy | IND cleared April 2025 | Summarised from the company's [10-K filed Mar 3, 2026](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm). ## Immunome annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$6.9 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | [$9.0 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | | Research and development | [$177.3 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | [$129.5 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | | Net income (loss) | [-$212.4 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | [-$293.0 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | | Cash from operations | [-$190.9 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | [-$110.8 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | | Cash and equivalents | [$653.5 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/) | [$143.4 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/) | [$74.0 million](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $217.7 million, plus short-term investments of $302.3 million, $520.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Immunome Has Immunome raised money recently? Our latest story on this, dated Dec 15, 2025: "Immunome proposes $400 million stock offering, later sets $21.50 price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunome-proposes-400-million-stock-offering-later-sets-21-50-price/). What is the ticker symbol of Immunome? Immunome, Inc. trades under the ticker IMNM on NASDAQ. Where is Immunome listed? Immunome, Inc. is listed on NASDAQ. What is the SEC CIK of Immunome? The SEC Central Index Key (CIK) for Immunome, Inc. is 1472012. Its filings are on SEC EDGAR. How many shares does Immunome have outstanding? 113,577,629 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Immunome listed under? Our directory records Immunome, Inc. under United States. What does Immunome do? Our directory classifies Immunome, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Immunome? The ISIN recorded for Immunome, Inc. is US45257U1088. Does aibio.space cover Immunome? aibio.space lists Immunome, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Immunome incorporated? SEC records list its state or country of incorporation as DE. What does Immunome develop? Immunome is a company with antibody-drug conjugate (ADC) and radioligand programs. Its clinical asset varegacestat, formerly AL102, is an investigational, oral, once-daily GSI therapy under evaluation for desmoid tumors. What is Varegacestat (formerly AL102) from Immunome? Varegacestat (formerly AL102): Oral once-daily GSI therapy for progressing desmoid tumors Stage: Phase 3. What is IM-3050 from Immunome? IM-3050: Fibroblast activation protein targeted radioligand therapy Stage: IND cleared April 2025. What was Immunome's revenue last year? $6.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Immunome profitable? Immunome, Inc. reported a net loss of $212.4 million for the fiscal year ended Dec 31, 2025, and used $190.9 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Immunome Members talk about Immunome (IMNM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Immunome, newest first. Each line links the filing it comes from. 1. 2026-10-05 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/d114908d8k.htm) 2. 2025-12-15 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1472012/000119312525319257/d792845d424b5.htm) 3. 2025-05-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_ex99-1.htm) 4. 2025-01-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1472012/000110465925007230/tm254657-2_424b5.htm) 5. 2024-11-22 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1472012/000110465924122081/tm2429121-1_s3asr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IMNM on TradingView](https://www.tradingview.com/symbols/NASDAQ-IMNM/). ## SEC filings and registration - **SEC name**: Immunome Inc. - **CIK**: 1472012 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: IMNM (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 18702 N. CREEK PARKWAY, BOTHELL, WA, 98011 - **Phone**: 610-321-3700 - **Shares outstanding**: 113,577,629 as of 2026-08-06 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/d114908d8k.htm) filed 2026-10-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/imnm-20260609.htm) filed 2026-06-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000119312526219425/imnm-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-20260512.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1472012/000114036126016685/ny20062786x1_def14a.htm) filed 2026-04-24 - [10-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm) filed 2026-03-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001472012), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Immunome, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMNM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Immunome, Inc. - **Ticker**: IMNM - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US45257U1088 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IMNM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/immunome/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Immunome (IMNM) news: offering", 2026-10-31, https://aibio.space/companies/immunome/